Literature DB >> 29373941

Nutritional status and nutritional risk in patients with neuroendocrine tumors.

Mette Borre1, Gitte Aarøe Dam1, Anne Wilkens Knudsen2, Henning Grønbaek1.   

Abstract

BACKGROUND: Malnutrition is frequent among patients with malignancies and associated with impaired function, reduced quality of life and increased mortality. Few data are available in patients with neuroendocrine tumors (NET) on nutritional status, nutritional risk, and nutrition impact symptoms (NIS). We aimed to assess nutritional status (NS) and risk, level of function and associations with NIS in NET patients.
METHODS: In a cross-sectional study of NET patients, we measured body mass index (BMI) and handgrip strength (HGS) as markers of NS and muscle function assessed by HGS. The nutritional risk score (NRS) was determined by NRS-2002. NIS was assessed by the eating symptoms questionnaire (ESQ), and disease-related appetite questionnaire (DRAQ).
RESULTS: We included 186 patients (51% women), median age 66 years. We observed low BMI (<20.5 kg/m2) in 12%, low HGS in 25%, and impaired level of function in 43% of the patients. About 38% were at nutritional risk, more frequent in patients with residual disease (45% versus 29%, p < .05). Both low HGS, impaired level of function and being at nutritional risk were associated with the NIS: Nausea, vomiting, stomach ache and dry mouth (p < .05) whereas poor appetite and early satiety were only associated with being at nutritional risk and having impaired level of function (p < .05, all).
CONCLUSIONS: Almost 40% of NET patients were at nutritional risk; and 25% had impaired HGS associated with specific NIS that preclude food intake. We recommend that NET outpatients are screened with NRS-2002 and that HGS and NIS are determined if NET patients need nutritional therapy.

Entities:  

Keywords:  Neuroendocrine tumor; cancer; eating symptoms questionnaire; hand grip strength; nutrition impact symptoms; nutritional risk score

Mesh:

Year:  2018        PMID: 29373941     DOI: 10.1080/00365521.2018.1430848

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Preoperative Muscle-Adipose Index: A New Prognostic Factor for Gastric Cancer.

Authors:  Jun Lu; Zhen Xue; Jian-Gao Xie; Bin-Bin Xu; Hai-Bo Yang; Dong Wu; Hua-Long Zheng; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Ping Li; Chang-Ming Huang; Chao-Hui Zheng
Journal:  Ann Surg Oncol       Date:  2022-03-16       Impact factor: 5.344

Review 2.  The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.

Authors:  Jakub Pobłocki; Anna Jasińska; Anhelli Syrenicz; Elżbieta Andrysiak-Mamos; Małgorzata Szczuko
Journal:  Nutrients       Date:  2020-05-15       Impact factor: 5.717

Review 3.  Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Barbara Altieri; Carla Di Dato; Roberta Modica; Filomena Bottiglieri; Antonella Di Sarno; James F H Pittaway; Chiara Martini; Antongiulio Faggiano; Annamaria Colao
Journal:  Nutrients       Date:  2020-04-08       Impact factor: 5.717

4.  Controlling Nutritional Status (CONUT) Score as a New Indicator of Prognosis in Patients With Hilar Cholangiocarcinoma Is Superior to NLR and PNI: A Single-Center Retrospective Study.

Authors:  Ankang Wang; Zhenxing He; Peng Cong; Yueyu Qu; Tao Hu; Yu Cai; Bo Sun; Hao Chen; Wenguang Fu; Yong Peng
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

5.  CT-derived body composition analysis could possibly replace DXA and BIA to monitor NET-patients.

Authors:  Lennard Kroll; Annie Mathew; Felix Nensa; Harald Lahner; Giulia Baldini; René Hosch; Sven Koitka; Jens Kleesiek; Christoph Rischpler; Johannes Haubold; Dagmar Fuhrer
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

6.  Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study.

Authors:  Ankang Wang; Bo Sun; Min Wang; Hao Shi; Zhiwei Huang; Tao He; Qiu Li; Jiaqi Deng; Wenguang Fu; Yu Jiang
Journal:  PeerJ       Date:  2020-03-18       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.